SynthesisDrug design, development and therapy2025
A Systematic Review of Population Pharmacokinetics, Safety, and Factors Influencing Trough Concentrations of Voriconazole in Asian Patients with Liver Dysfunction.
Synthesis in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study systematically reviews recent research on voriconazole (VRC) use in Asian patients with liver dysfunction to provide a scientific basis for individualized therapy. Methods: A comprehensive literature search was conducted in EMBASE, PubMed, Web of Science, and the Cochrane Library for clinical studies on VRC use in Asian patients with liver dysfunction, published between January 1, 2000, and March 1, 2025. Studies meeting the inclusion and exclusion criteria were analyzed to summarize VRC safety, factors influencing trough concentrations ( Results: A total of 14 studies were included, comprising 9 studies on the safety of VRC in patients with liver dysfunction, 5 studies investigating factors affecting VRC Conclusion: Therapeutic drug monitoring (TDM) and PPK studies can aid in optimizing VRC dosing, ensuring safer and more effective individualized therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.